THEMIS2 may serve as a novel marker for immune infiltration in thyroid cancer by activating the p53 and JAK-STAT signaling pathways, inhibiting T-cell activation, and facilitating the occurrence and progression of thyroid cancer. This evidence concerns the gene TP53 and thyroid cancer.